Ketamine and Midazolam Infusions for CRPS: Feasibility Study
WithdrawnPhase 2NCT05945147
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).
Study details
- Official title
- Feasibility Study Comparing a Ketamine and Midazolam Infusion to a Midazolam-Only Infusion for Complex Regional Pain Syndrome
- Conditions
- Interventions
- Sponsor
- Stanford University
- Start date
- 2099-01-01
- Primary completion
- 2099-04-30
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
* Age 18 to 65 years * Meets the International Association for the Study of Pain (IASP) diagnostic criteria for complex regional pain syndrome (CRPS) * Primary complaint of CRPS-attributable pain for ≥3 months * Average pain intensity of ≥3/10 over the last month * Can read and comprehend English-language questionnaires * Can receive text messages by phone * Can identify a responsible adult who can provide transportation to and from infusion site for 5 consecutive days (Mon-Fri)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05945147